Compare SRPT & PBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRPT | PBH |
|---|---|---|
| Founded | 1980 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | 2000 | 2004 |
| Metric | SRPT | PBH |
|---|---|---|
| Price | $16.17 | $48.92 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 29 | 3 |
| Target Price | $25.85 | ★ $75.33 |
| AVG Volume (30 Days) | ★ 2.8M | 629.9K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 2.88 | ★ 3.91 |
| Revenue | ★ $2,198,237,000.00 | $975,777,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.31 |
| P/E Ratio | ★ $5.56 | $12.07 |
| Revenue Growth | 15.58 | ★ 36.77 |
| 52 Week Low | $10.42 | $42.62 |
| 52 Week High | $25.32 | $81.65 |
| Indicator | SRPT | PBH |
|---|---|---|
| Relative Strength Index (RSI) | 43.75 | 52.96 |
| Support Level | $15.10 | $44.51 |
| Resistance Level | $18.16 | $49.51 |
| Average True Range (ATR) | 0.79 | 1.77 |
| MACD | 0.18 | 0.39 |
| Stochastic Oscillator | 42.57 | 78.21 |
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.